Literature DB >> 11269976

Transaminitis in Duchenne's muscular dystrophy.

S K Tay1, H T Ong, P S Low.   

Abstract

BACKGROUND: Persistently raised transaminase levels often prompt the clinician to investigate for liver pathology. Previously, some of our patients with Duchenne's muscular dystrophy have had investigations to look for liver disorders when the alanine transaminases (ALTs) were found incidentally to be high. AIM: The objective of the study was to ascertain the levels of the transaminases in patients with Duchenne's muscular dystrophy and to see if the levels of transaminases correlated with muscle enzymes such as creatine kinase (CK).
MATERIALS AND METHODS: This is a case series of 19 patients with Duchenne's muscular dystrophy. Alanine and aspartate transaminase (AST) levels and CK levels were measured in the serum of the patients.
RESULTS: In this series, ALT and AST levels were all found to be raised significantly in patients with biopsy-proven Duchenne's muscular dystrophy and Becker's muscular dystrophy. Alanine transaminase, in particular, was raised to a mean of 356 mmol/L, 9 times above the mean for normal. There was also good correlation between ALT and CK levels with a correlation coefficient of r = 0.80 and P value 0.01. Similar to CK, the transaminase levels were inversely proportional to mobility and to age.
CONCLUSION: The presence of hypertransaminasemia in patients with muscular dystrophy should be attributed to muscle breakdown rather than to liver pathology and such patients should not be over-investigated for liver disease. In the absence of liver pathology, raised transaminases may be an early sign of occult muscular dystrophy and such patients should have CK levels checked to look for evidence of muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11269976

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  8 in total

1.  All that glitters is not gold: elevated liver enzymes do not mean liver disease always.

Authors:  Jeyamani Ramachandran; K G Sajith
Journal:  Indian J Gastroenterol       Date:  2014-01-14

2.  Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA.

Authors:  Roni Lehmann-Werman; Judith Magenheim; Joshua Moss; Daniel Neiman; Ofri Abraham; Sheina Piyanzin; Hai Zemmour; Ilana Fox; Talya Dor; Markus Grompe; Giora Landesberg; Bao-Li Loza; Abraham Shaked; Kim Olthoff; Benjamin Glaser; Ruth Shemer; Yuval Dor
Journal:  JCI Insight       Date:  2018-06-21

3.  Elevated serum aminotransferases secondary to rippling muscle disease.

Authors:  Kumanan Nalankilli; John Lubel
Journal:  Case Rep Gastroenterol       Date:  2013-05-24

4.  Serum Enzyme Profiles Differentiate Five Types of Muscular Dystrophy.

Authors:  Yuling Zhu; Huili Zhang; Yiming Sun; Yaqin Li; Langhui Deng; Xingxuan Wen; Huaqiao Wang; Cheng Zhang
Journal:  Dis Markers       Date:  2015-04-29       Impact factor: 3.434

5.  Influence of ShuJinHuoXue tablets on ischemia reperfusion injury of animals' skeletal muscle.

Authors:  Zhihong Tong; Fang Yu; Zhonghua Liu; Haidong Liang
Journal:  Molecules       Date:  2012-07-16       Impact factor: 4.411

6.  The Expanding Spectrum of Dystrophinopathies: HyperCKemia to Manifest Female Carriers.

Authors:  Renu Suthar; Shivan Kesavan; Indar K Sharawat; Manisha Malviya; Titiksha Sirari; Bhupendra K Sihag; Arushi G Saini; Vishalavath Jyothi; Naveen Sankhyan
Journal:  J Pediatr Neurosci       Date:  2021-07-02

7.  Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

Authors:  Richard S Finkel; Kevin M Flanigan; Brenda Wong; Carsten Bönnemann; Jacinda Sampson; H Lee Sweeney; Allen Reha; Valerie J Northcutt; Gary Elfring; Jay Barth; Stuart W Peltz
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

8.  Effects of Folinic Acid Administration on Lower Limb Ischemia/Reperfusion Injury in Rats.

Authors:  Iñigo Cearra; Borja Herrero de la Parte; Inmaculada Ruiz Montesinos; Ana Alonso-Varona; Diana Isabel Moreno-Franco; Ignacio García-Alonso
Journal:  Antioxidants (Basel)       Date:  2021-11-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.